drugset
drugset / Trial / NCT03955666

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

NCT03955666 ↗

Phase 1 Completed 16 enrolled Provention Bio, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

This Phase 1b study will evaluate the safety of PRV-3279 in healthy adult subjects

Timeline

Start
2019-08-07
Primary completion
2019-12-11
Completion
2019-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MGD010 Unknown — Intravenous

Indications

No indication recorded.